Case report

The Risk of Hypercoagulability in Ovarian Hyperstimulation Syndrome

Damir Danolić ; Department of Gynecologic Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Miro Kasum ; Clinical Department of Obstetrics and Gynecology, Zagreb University Hospital Center, Zagreb, Croatia
Mario Puljiz ; Department of Gynecologic Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Ilija Alvir ; Department of Gynecologic Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Darko Tomica ; Department of Gynecologic Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Ivica Mamić ; Department of Gynecologic Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Ermin Čehić ; Department of Obstetrics and Gynecology, Zenica Cantonal Hospital, Zenica, Bosnia and Herzegovina
Ivan Bolanča ; Clinical Department of Obstetrics and Gynecology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia

Abstract

Ovarian hyperstimulation syndrome (OHSS) is a rare and potentially life-threatening complication of infertility treatment occurring during either the luteal phase or early pregnancy. An increasing number of thromboembolic complications associated with the increased use of assisted reproductive techniques have been reported in the literature. Identification of the risk factors is crucial for prevention of thromboembolic events in OHSS patients. Alterations in the hemostatic system cause hypercoagulability in women affected by severe OHSS. Coexistence of inherited hypercoagulable conditions increases the risk of thromboembolism. The role of clinical parameters that can help predict development of thrombosis is controversial. Patients with a personal or family history of thrombosis undergoing infertility treatment should be considered for thrombophilia screening, while routine examination of inherited thrombophilic mutations is not indicated in infertile patients. Antithrombotic primary prevention is not indicated in healthy women undergoing assisted reproductive procedures or in women with thrombophilia. Anticoagulant therapy is indicted if there is clinical evidence of thrombosis or laboratory evidence of hypercoagulability. In this review, the risks of hypercoagulability in the OHSS are discussed.

Keywords

Ovarian hyperstimulation syndrome; Thrombophilia; Thrombosis

Hrčak ID:

145479

URI

https://hrcak.srce.hr/145479

Publication date:

1.7.2015.

Article data in other languages: croatian

Visits: 2.181 *